A Stuetz
Overview
Explore the profile of A Stuetz including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
5
Citations
53
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Kalthoff F, Chung J, Musser P, Stuetz A
Clin Exp Immunol
. 2003 Aug;
133(3):350-9.
PMID: 12930360
Clinically, corticosteroids (CS) are among the first line drugs in the therapy of autoimmune and allergic diseases and potently inhibit the activation of immune cells. However, due to their pleiotropic...
2.
Kalthoff F, Chung J, Stuetz A
Clin Exp Immunol
. 2002 Sep;
130(1):85-92.
PMID: 12296857
Pimecrolimus is a new non-steroidal inhibitor of T cell and mast cell activation. In the present study, we compared the potency of pimecrolimus and cyclosporin A (CyA) to inhibit cytokine...
3.
Stuetz A, Grassberger M, Meingassner J
Semin Cutan Med Surg
. 2002 Jan;
20(4):233-41.
PMID: 11770910
The ascomycin macrolactam derivative pimecrolimus (Elidel, SDZ ASM 981; Novartis Pharma AG, Basel Switzerland) is a cell-selective inhibitor of inflammatory cytokines specifically developed for the treatment of inflammatory skin diseases,...
4.
Schuster I, Egger H, Bikle D, Herzig G, Reddy G, Stuetz A, et al.
Steroids
. 2001 Feb;
66(3-5):409-22.
PMID: 11179750
Human keratinocytes convert 25(OH)D(3) to hormonally active 1alpha,25(OH)(2)D(3) and respond to its antiproliferative/prodifferentiating action in vitro and in vivo. Levels and activity of 1alpha,25(OH)(2)D(3) are short-lived. 1alpha,25(OH)(2)D(3) induces 24-hydroxylase (CYP24)...
5.
Paul C, Graeber M, Stuetz A
Expert Opin Investig Drugs
. 2000 Nov;
9(1):69-77.
PMID: 11060661
Ascomycin derivatives represent a novel class of anti-inflammatory macrolactams currently under development for the treatment of skin diseases. The main biological effect of ascomycins is an inhibition of the synthesis...